Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Core Viewpoint - The market anticipates Mirum Pharmaceuticals, Inc. (MIRM) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Financial Expectations - The consensus estimate indicates a quarterly loss of $0.31 per share, reflecting a year-over-year improvement of +40.4%. Revenues are projected to reach $108.4 million, representing a 39.2% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised 6.92% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Potential - The Most Accurate Estimate for Mirum Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.65%, suggesting a strong likelihood of beating the consensus EPS estimate [12]. - Historical performance shows that Mirum Pharmaceuticals has beaten consensus EPS estimates in two out of the last four quarters, with a notable surprise of +23.08% in the last reported quarter [13][14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Tango Therapeutics, Inc. (TNGX) is expected to report a loss of $0.35 per share for the same quarter, indicating a year-over-year decline of -45.8%. Revenue expectations for Tango are $6.19 million, down 68.9% from the previous year [18][19]. - Tango Therapeutics has a Zacks Rank of 2 (Buy) and an Earnings ESP of +0.57%, suggesting a likelihood of surpassing the consensus EPS estimate [20].